Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
OrthoPediatrics (KIDS): Can the Stock Reach a $37 Target?

OrthoPediatrics (KIDS): Can the Stock Reach a $37 Target?

Key Takeaways

  • The central target of $37 reflects the average of the two current analyst price targets that sit above the latest market price, not a full consensus figure.
  • Across eight verified analyst targets, the range is $27 to $38, with an overall mean of roughly $30.75 — essentially at or below the recent share price.
  • With shares recently near $30.87, reaching $37 would require an advance of about 20%, a substantial move.
  • Record third-quarter revenue, a raised full-year outlook, and an expanding pediatric product portfolio are the strongest supporting factors.
  • The biggest risks are a valuation that has already rerated sharply, continued net losses, and analyst targets that have not kept pace with the rally.
  • For more context on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
  • Explore Trending AI Robots for AI-driven market analysis across thousands of stocks and ETFs.

Analyst Price Targets and Consensus View

OrthoPediatrics Corp. (KIDS), a Warsaw, Indiana-based medical device maker focused exclusively on pediatric orthopedics, is covered by eight analysts with a consensus rating of Buy. Their individual 12-month price targets range from a low of $27 (Stifel) to a high of $38 (Lake Street), with an overall mean of approximately $30.75. Because that mean sits essentially at or below the latest share price, it fails to provide a meaningful upside target.

Applying a minimum-distance standard, only two of the eight targets remain above the current price: $35 and $38. Their average is $36.50, rounded to $37, which serves as the central target for this analysis. This is the average of analyst targets above the current price, not an official consensus; the full average of all eight targets ($30.75) and the complete range ($27–$38) are provided for context. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Views differ sharply. Hold-rated Truist argues the stock trades at a valuation premium versus peers that already reflects its growth and emerging profitability. More bullish firms such as TD Cowen, Canaccord, Piper Sandler, BTIG, and Lake Street point to strong top-line momentum, new product contributions, and a multi-year growth runway. Recent actions have been broadly positive, with several firms raising targets after third-quarter results.

Current Market Position and Path Toward the Target

Shares of KIDS recently closed near $30.87, just below a 52-week high around $32.62, after a powerful multi-month rally. Reaching the $37 central target would require a rise of roughly 20%, a substantial move from current levels.

The path is supported by fundamental momentum: third-quarter 2026 revenue of $72.7 million rose 19% year over year, and management raised full-year revenue guidance to $270–$273 million, implying 14–16% growth. Adjusted EBITDA reached a record $6.9 million, and free cash flow turned positive. Still, the company remains unprofitable on a GAAP basis, posting a net loss of $5.9 million, or $0.25 per share, in the quarter.

What Could Support a Move Toward the Target

Several factors could support a continued advance. OrthoPediatrics is in what management calls an innovation "Super Cycle," with new products such as the 3P Hip plating system, Traxio, and VerteGlide beginning to contribute revenue. Its specialty bracing franchise (OPSB) grew more than 20%, with over 60 clinics and 34 product systems. International revenue rose 18%, aided by new European launches following regulatory approvals.

Critically, the company is improving its financial profile: 74% gross margins, record adjusted EBITDA, positive free cash flow, and guidance for breakeven free cash flow in 2026 and positive free cash flow in 2027. Analyst revisions have been mostly upward, and consensus sentiment remains Buy.

What Could Prevent the Target From Being Reached

The principal obstacle is valuation. The stock's sharp run — roughly a 91% one-year gain — has outpaced analyst targets, leaving the broader sell-side mean below the current price. Persistent GAAP net losses and an EPS that remains negative mean the stock is still priced on growth expectations rather than current profitability.

Other risks include margin pressure from the lower-margin bracing business, elevated sales and marketing spending (up 24% year over year), foreign-exchange and Latin America set-sales headwinds, and the inherent uncertainty of commercializing many new products simultaneously. If execution slips or multiple expansion stalls, the stock could consolidate well short of $37.

Technical Levels and Market Structure

From a technical standpoint, KIDS trades just under its 52-week high near $32.62, which now acts as the immediate resistance level. A decisive move through that area would clear a meaningful overhead milestone on the way toward the $37 target. On the downside, the pre-earnings consolidation zone near $24–$25 represents a potential support level, with the psychological $30 mark serving as nearer-term support. The long-term trend is decisively upward after recovering from a 52-week low near $14.42.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary in their methodology and timeline. Investors should watch upcoming quarterly results, further full-year guidance updates, new product launch progress (including the transition from limited to full commercial release), adjusted EBITDA and free cash flow trajectory, and any additional analyst target revisions. Macroeconomic factors such as hospital procedure volumes, interest rates, and currency moves may also influence the path.

Using Tickeron’s AI Daily Buy/Sell Signals

I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals grounded in technical behavior and market conditions. For a stock where momentum and valuation are both in focus, it helps me track trend shifts and position changes more efficiently than manual review alone. Traders looking for a structured edge can incorporate these signals into their broader research process.

Final Assessment

The question of whether OrthoPediatrics (KIDS) can reach $37 hinges on whether its fundamental momentum can extend a rally that has already outpaced most analyst expectations. The $37 figure represents the average of the two analyst targets above the current price, against an overall mean of $30.75 and a range of $27 to $38. That wide dispersion underscores genuine disagreement: bulls see a multi-year product cycle driving sustained growth, while skeptics argue the valuation already reflects the optimism. Reaching $37 would require roughly a 20% advance from recent levels — substantial but not unprecedented for a stock posting 19% revenue growth and improving cash flow. Investors should monitor execution on new product launches, progress toward profitability, and whether analyst targets catch up to the share price.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: KIDS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


KIDS's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for KIDS moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KIDS as a result. In 70 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for KIDS turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KIDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

KIDS broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 67 cases where KIDS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

KIDS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KIDS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where KIDS advanced for three days, in 218 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 98 of 130 cases where KIDS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.413) is normal, around the industry mean (4.142). P/E Ratio (-18.905) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.175) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KIDS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KIDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of orthopedic devices

Industry MedicalNursingServices

Industry
Medical Specialties
Address
2850 Frontier Drive
Phone
+1 574 268-6379
Employees
602
Web
https://www.orthopediatrics.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.